Search Results

There are 6720 results for: content related to: eGFR decrease during antiviral C therapy with first generation protease inhibitors: a clinical significance?

  1. You have free access to this content
    Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers

    Hepatology

    Volume 56, Issue 5, November 2012, Pages: 1622–1630, Ellen Hulskotte, Samir Gupta, Fengjuan Xuan, Marga van Zutven, Edward O'Mara, Hwa-Ping Feng, John Wagner and Joan Butterton

    Version of Record online : 14 OCT 2012, DOI: 10.1002/hep.25831

  2. You have free access to this content
    Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?

    Liver International

    Volume 32, Issue s1, February 2012, Pages: 54–60, Mitchell L. Shiffman and Rafael Esteban

    Version of Record online : 29 DEC 2011, DOI: 10.1111/j.1478-3231.2011.02718.x

  3. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C

    Journal of Viral Hepatitis

    Volume 19, Issue s2, May 2012, Pages: 1–26, I. M. Jacobson, J.-M. Pawlotsky, N. H. Afdhal, G. M. Dusheiko, X. Forns, D. M. Jensen, F. Poordad and J. Schulz

    Version of Record online : 8 MAR 2012, DOI: 10.1111/j.1365-2893.2012.01590.x

  4. Boceprevir in liver transplant recipients

    Liver International

    Volume 35, Issue 1, January 2015, Pages: 192–197, Sammy Saab, Vignan Manne, Sherona Bau, Justin A. Reynolds, Ruby Allen, Leonard Goldstein, Francisco Durazo, Mohammed El-Kabany, Steven Han and Ronald W. Busuttil

    Version of Record online : 10 APR 2014, DOI: 10.1111/liv.12548

  5. Boceprevir: A Novel NS3/4 Protease Inhibitor for the Treatment of Hepatitis C

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 32, Issue 2, February 2012, Pages: 173–190, Olga M. Klibanov, Stephen B. Vickery, Jacqueline L. Olin, Lisa S. Smith and Shannon H. Williams

    Version of Record online : 30 JAN 2012, DOI: 10.1002/PHAR.1046

  6. Use of first-generation HCV protease inhibitors in patients coinfected by HIV and HCV genotype 1

    Liver International

    Volume 34, Issue 6, July 2014, Pages: 869–889, Dominique Salmon-Ceron, Cédric Arvieux, Marc Bourlière, Patrice Cacoub, Philippe Halfon, Karine Lacombe, Georges-Philippe Pageaux, Gilles Pialoux, Lionel Piroth, Isabelle Poizot-Martin, Eric Rosenthal and Stanislas Pol

    Version of Record online : 25 NOV 2013, DOI: 10.1111/liv.12363

  7. You have free access to this content
    HCV Therapeutics: Approved Agents

    Hepatology

    Volume 58, Issue S1, October 2013, Pages: 1091A–1168A,

    Version of Record online : 15 OCT 2013, DOI: 10.1002/hep.26880

  8. Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b

    Journal of Viral Hepatitis

    Volume 19, Issue 2, February 2012, Pages: 120–127, J. Vermehren, S. Susser, C. M. Lange, N. Forestier, U. Karey, E. Hughes, R. Ralston, X. Tong, S. Zeuzem and C. Sarrazin

    Version of Record online : 1 MAR 2011, DOI: 10.1111/j.1365-2893.2011.01449.x

  9. You have free access to this content
    Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1

    Liver International

    Volume 32, Issue s1, February 2012, Pages: 27–31, Michael P. Manns, Antoaneta A. Markova, Beatriz Calle Serrano and Markus Cornberg

    Version of Record online : 29 DEC 2011, DOI: 10.1111/j.1478-3231.2011.02725.x

  10. You have free access to this content
    Future treatment of patients with HCV cirrhosis

    Liver International

    Volume 32, Issue s1, February 2012, Pages: 113–119, Marc Bourlière, Asma Khaloun, Claire Wartelle-Bladou, Valérie Oules, Isabelle Portal, Souad Benali, Xavier Adhoute and Paul Castellani

    Version of Record online : 29 DEC 2011, DOI: 10.1111/j.1478-3231.2011.02702.x

  11. You have free access to this content
    How to optimize HCV therapy in genotype 1 patients with cirrhosis

    Liver International

    Volume 33, Issue s1, February 2013, Pages: 46–55, Marc Bourlière, Astrid Wendt, Hélène Fontaine, Christophe Hézode, Stanislas Pol and Jean Pierre Bronowicki

    Version of Record online : 3 JAN 2013, DOI: 10.1111/liv.12067

  12. You have free access to this content
    Phase III results in Genotype 1 naïve patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin

    Liver International

    Volume 32, Issue s1, February 2012, Pages: 39–43, Paul Y. Kwo

    Version of Record online : 29 DEC 2011, DOI: 10.1111/j.1478-3231.2011.02709.x

  13. Uptake and utilization of directly acting antiviral medications for hepatitis C infection in U.S. veterans

    Journal of Viral Hepatitis

    Volume 22, Issue 5, May 2015, Pages: 489–495, R. Gidwani, P. G. Barnett, J. D. Goldhaber-Fiebert, S. M. Asch, J. Lo, S. K. Dally and D. K. Owens

    Version of Record online : 24 NOV 2014, DOI: 10.1111/jvh.12344

  14. Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients

    Liver International

    Volume 35, Issue 9, September 2015, Pages: 2090–2099, Patrick Miailhes, Camille Gilbert, Karine Lacombe, Joop E. Arends, Massimo Puoti, Jürgen K. Rockstroh, Philippe Sogni, Hélène Fontaine, Eric Rosenthal, Maria Winnock, Marc-Arthur Loko, Linda Wittkop, François Dabis, Dominique Salmon and the ESCMID European Study Group on Viral Hepatitis

    Version of Record online : 23 FEB 2015, DOI: 10.1111/liv.12799

  15. Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis

    Liver International

    Volume 35, Issue 1, January 2015, Pages: 90–100, Jose L. Calleja, Juan M. Pascasio, Belén Ruiz-Antorán, Francisco Gea, Rafael Bárcena, Juan R. Larrubia, Ramón Pérez-Álvarez, Jose M. Sousa, Manuel Romero-Gómez, Ricard Solá, Juan de la Revilla, Javier Crespo, Jose M. Navarro, Juan I. Arenas, Manuel Delgado, Conrado M. Fernández-Rodríguez, Ramon Planas, Maria Buti, Xavier Forns and the Spanish Group for the Study of the Use of Direct-Acting Drugs Hepatitis C with Severe Fibrosis

    Version of Record online : 15 SEP 2014, DOI: 10.1111/liv.12656

  16. You have free access to this content
    Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow

    Liver International

    Volume 32, Issue s1, February 2012, Pages: 88–102, Tarik Asselah and Patrick Marcellin

    Version of Record online : 29 DEC 2011, DOI: 10.1111/j.1478-3231.2011.02699.x

  17. You have full text access to this OnlineOpen article
    Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir

    British Journal of Clinical Pharmacology

    Volume 78, Issue 5, November 2014, Pages: 1043–1049, Mark Johnson, Julie Borland, Shuguang Chen, Paul Savina, Brian Wynne and Stephen Piscitelli

    Version of Record online : 20 OCT 2014, DOI: 10.1111/bcp.12428

  18. You have free access to this content
    Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?

    Liver International

    Volume 32, Issue s1, February 2012, Pages: 79–87, Philippe Halfon and Christoph Sarrazin

    Version of Record online : 29 DEC 2011, DOI: 10.1111/j.1478-3231.2011.02716.x

  19. Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings

    Journal of Viral Hepatitis

    Volume 22, Issue 9, September 2015, Pages: 691–700, A. A. Butt, P. Yan, O. S. Shaikh, M. S. Freiberg, V. Lo Re III, A. C. Justice, K. E. Sherman and for the ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) Study Team

    Version of Record online : 18 DEC 2014, DOI: 10.1111/jvh.12375

  20. You have free access to this content
    Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort

    Alimentary Pharmacology & Therapeutics

    Volume 39, Issue 1, January 2014, Pages: 93–103, L. I. Backus, P. S. Belperio, T. A. Shahoumian, R. Cheung and L. A. Mole

    Version of Record online : 10 NOV 2013, DOI: 10.1111/apt.12546